1. Generics Bulletin
  3. >>Biosimilars

First US Lucentis Biosimilar Expected By Year End, Roche Confirms

Samsung Bioepis’ SB11 Biosimilar Pending With FDA

 
• By Dean Rudge

Another of Roche’s biologic blockbusters is due to bite the dust this year, the originator has confirmed, with biosimilar competition to Lucentis forecast in the second half of 2021.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Samsung Bioepis' SB11 candidate is pending approval with the USFDA • Source: Shutterstock

Roche has confirmed that the first biosimilar to its Lucentis (ranibizumab) eye-disease biologic is expected to launch in the US in the second half of 2021.

Buried within the originator’s first-quarter 2021 presentation, Roche notes, “first biosimilar expected in H2,” alongside commentary that while product sales had declined due to

More from Biosimilars

More from Products